Exciting New Research and Treatments for Leukemia
Scientists have identified a specific type of stem-cell that is present at the time of diagnosis that makes certain AML patients resistant to different therapies.
In a recent clinical trial the drug Ceplene showed positive results in preventing relapse in AML patients.
A look at recent studies that have examined the effectiveness of using Idarubicin and Daunorubicin as a course of treatment for AML.
A study published by the New England Journal of Medicine using Midostaurin in conjunction with chemotherapy found that is provided a significant benefit to the survival of AML patients with the FLT3 mutation.
Phase 1 of a new AML drug study shows that it it has the desired safety and it shows signs of tolerability in patients in varying dosage levels.